You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,964,402


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,964,402
Title:Methods for culture and production of single cell populations of human embryonic stem cells
Abstract: We used Accutase.TM., a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, Accutase treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with Accutase to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. Accutase-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.
Inventor(s): Terskikh; Alexey (San Diego, CA), Bajpai; Ruchi (Redwood City, CA)
Assignee: Sanford-Burnham Medical Research Institute (La Jolla, CA)
Application Number:11/807,223
Patent Claims:1. A method of preparing human embryonic stem cells comprising (a) providing a culture of human embryonic stem (ES) cells and (b) enzymatically dissociating the culture of human embryonic stem cells using a mixture of enzymes with proteolytic, collagenolytic, and DNAse activities to produce a plurality of single embryonic stem cells, wherein greater than 75 percent of said plurality of single embryonic stem cells are viable and pluripotent, and wherein the single embryonic stem cells do not experience a decrease in plating efficiency upon repeated passaging when compared to single human ES cells that are dissociated without the use of a mixture of enzymes with proteolytic, collagenolytic, and DNAse activities, and wherein a greater proportion of said plurality of single ES cells are undifferentiated when compared to ES cells produced by collagenase digestion of a culture of ES cells.

2. The method of claim 1 wherein greater than 80 percent of said plurality of single embryonic stem cells are viable and pluripotent.

3. The method of claim 1 wherein greater than 85 percent of said plurality of single embryonic stem cells are viable and pluripotent.

4. The method of claim 1 wherein greater than 90 percent of said plurality of single embryonic stem cells are viable and pluripotent.

5. The method of claim 1 wherein said single embryonic stem cells are karyotypically normal.

6. The method of claim 1 comprising flow-sorting said plurality of single embryonic stem cells.

7. The method of claim 1 comprising depositing at least one of said single embryonic stem cells into a well of a multi-well plate.

8. The method of claim 1 comprising flow-sorting said plurality of single embryonic stem cells to provide a flow-sorted embryonic stem cell and depositing the flow-sorted embryonic stem cell into a well of a multi-well plate.

9. The method of claim 1 further comprising replating the single embryonic stem cells at a lower density and culturing the cells until they form a monolayer.

10. The method of claim 1 further comprising growing a plurality of cultures of embryonic stem cells from said plurality of single embryonic stem cells.

11. The method of claim 10 wherein said plurality of cultures of embryonic stem cells has substantially uniformly undifferentiated morphology.

12. An automated method of claim 1, further comprising using flow cytometry to automatically sort said plurality of said single embryonic stem cells and/or dispense such cells into separate wells of a cell culture dish.

13. A method of passaging embryonic stem cells comprising (a) providing a culture of human embryonic stem cells in a first culture vessel; (b) dissociating the culture of human embryonic stem cells (ES) enzymatically using a mixture of enzymes with proteolytic, collagenolytic, and DNAse activities to produce a plurality of single embryonic stem cells, wherein greater than 75 percent of said plurality of single embryonic stem cells are viable and pluripotent; (c) transferring one or more of said single embryonic stem cells to a second culture vessel; and (d) growing a culture of embryonic stem cells from said one or more single embryonic stem cell in the second culture vessel, and wherein the single embryonic stem cells do not experience a decrease in plating efficiency upon repeated passaging when compared to single human ES cells that are dissociated without the use of a mixture of enzymes with proteolytic, collagenolytic. and DNAse activities, and wherein a greater proportion of said plurality of single ES cells are undifferentiated when compared to ES cells produced by collagenase digestion of a culture of ES cells.

14. The method of claim 13 wherein the culture in the first culture vessel is dissociated to produce said plurality of single embryonic stem cells without mechanical dissociation.

15. The method of claim 13 comprising flow-sorting the plurality of single embryonic stem cells.

16. The method of claim 15 comprising identifying a single embryonic stem cell having a desired phenotype and depositing the single embryonic stem cell having the desired phenotype in a second culture vessel.

17. The method of claim 13 comprising repeating steps (b)-(d).

18. The method of claim 13 wherein the first culture vessel or second culture vessel or both is a well of a multi-well plate.

19. An automated method of claim 13, further comprising using flow cytometry to automatically sort said plurality of said single embryonic stem cells and/or dispense such cells into separate wells of a cell culture dish.

20. The method of claim 13 wherein the culture in the second culture vessel forms a monolayer.

21. The method of claim 1 further comprising counting the single embryonic stem cells via machine.

22. The method of claim 13 further comprising counting the single embryonic stem cells via machine.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.